Tim Davis (Regional Head, UK Primary Markets at London Stock Exchange Group)

Tim Davis

Regional Head, UK Primary Markets at London Stock Exchange Group
Tim Haines (Executive Partner at Abingworth)

Tim Haines

Executive Partner at Abingworth

Tim has more than 30 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth Tim has taken Chair and board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Sientra, Scorpion, Venatorx and Adaptate Biotherapeutics.

Before joining Abingworth in 2005 he was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. Tim was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Tim was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD. He is on the Investment Advisory Board of Oxford University Innovation and is a former Director of the BIA, the BVCA Venture Committee and sat on the Wellcome Trust / NHS Health Innovation Challenge Fund.

Patrik Frei (CEO of Venture Valuation)

Patrik Frei

CEO of Venture Valuation
Jenny Button (Founder and CEO of Emm)

Jenny Button

Founder and CEO of Emm
Zoë Johnson (M:M Bio)

Zoë Johnson

M:M Bio
Irina Babina (CEO of Concr)

Irina Babina

CEO of Concr
Catherine Bacon (CEO of FingerPost)

Catherine Bacon

CEO of FingerPost
Jenny Bailey Cooper (CEO of Ferryx)

Jenny Bailey Cooper

CEO of Ferryx
Emma Thorp (Founder & Coach of Thorp Coaching)

Emma Thorp

Founder & Coach of Thorp Coaching

Emma is the Founder of Thorp Coaching, where she empowers leaders to achieve their goals while staying true to purpose, connection, and joy. With decades of leadership experience, including roles as Chief Commercial Officer and founder of a successful consulting business.
As Co-Founder of the Diverse Directors Programme, Emma champions diversity in boardrooms, preparing underrepresented leaders for Non-Executive Director roles. Her nature-inspired, intuitive coaching approach helps leaders navigate challenges and develop winning mindsets. On the panel “The Humble CEO – What Makes a Winning Mindset”, Emma will explore fostering resilience, embracing humility, and unlocking purpose-led leadership.

David Beadle (CEO of APOBEC Discovery Ltd.)

David Beadle

CEO of APOBEC Discovery Ltd.
Bharat Chudasama (Vice President, Head of Strategic Partnerships at Syneos Health)

Bharat Chudasama

Vice President, Head of Strategic Partnerships at Syneos Health
Francesca Cordeiro (Founder & CEO of Novai)

Francesca Cordeiro

Founder & CEO of Novai

Professor M Francesca Cordeiro, is a clinician-scientist, Chair of Ophthalmology Imperial College London, and UCL Professor, Honorary Consultant Ophthalmologist/Research Lead, Director of the ICORG Clinical Trials Unit at the Western Eye Hospital London, and recently Founder and Director of Novai Ltd, a start-up company based on DARC Technology.

Her research, funded continuously by the Wellcome Trust since 1996, focuses on novel and translational approaches with a target of saving sight and reducing disability, with over 180 peer-reviewed publications.

She has received a number of international awards for this work, including the Lewis Rudin Glaucoma Prize 2005, the Research to Prevent Blindness International Research Scholar Award 2015, the GG2 Diversity Award for Outstanding Achievement in Medicine 2017 and 2019 Duke Elder Award (Royal College of Ophthalmologists) and is frequently asked to give keynote lectures abroad.

Simon Bornschein (Founder & Chief Executive Officer of Coding Bio)

Simon Bornschein

Founder & Chief Executive Officer of Coding Bio
Andrew Craig (Founder of Plain English Finance)

Andrew Craig

Founder of Plain English Finance
Peter Dines (Managing Director of Mercia Ventures)

Peter Dines

Managing Director of Mercia Ventures
Neciah Dorh (CEO of FluoretiQ)

Neciah Dorh

CEO of FluoretiQ
Steve Emery (CSO at Chain Biotechnology)

Steve Emery

CSO at Chain Biotechnology
William Finch (CEO of Oxford Vacmedix UK)

William Finch

CEO of Oxford Vacmedix UK

After graduating from Oxford in Biochemistry William has over 34 years experience in the Biotech sector with a particular focus on leading SMEs.

Previous companies include R&D Systems, Amersham International, British Biotech and Beckman Coulter alongside small start-ups following outsourcing strategies where relevant.

James Fry (Partner - Head of Life Sciences at Mills and Reeve LLP)

James Fry

Partner - Head of Life Sciences at Mills and Reeve LLP

James is a partner at the law firm Mills & Reeve and heads the firm's life sciences sector. James is an experienced commercial and IP transactions lawyer with significant experience across the life sciences, including biotech, pharma and medical technologies. He regularly advises biotech and biopharma organisations on out-licensing and in-licensing transactions, broader partnering transactions, and on product development and commercialisation.

KIRAN GULATI (Director, Business Operations of New England Biolabs (UK))

KIRAN GULATI

Director, Business Operations of New England Biolabs (UK)
Jonathan Heeney (Founder & Chief Executive Officer of DIOSynVax)

Jonathan Heeney

Founder & Chief Executive Officer of DIOSynVax
Nicola Heron (Chief Strategy Officer at Medicines Discovery Catapult)

Nicola Heron

Chief Strategy Officer at Medicines Discovery Catapult
Jacob Hurst (Co-Founder & Chief Technology Officer of Etcembly)

Jacob Hurst

Co-Founder & Chief Technology Officer of Etcembly

Jacob Hurst, is the co-founder and CTO of Etcembly. Within Etcembly he helped pioneer the informatics techniques that have resulted in Etcembly being the second company in the world to affinity enhance a TCR to pM level and the first company to do so entirely by informatics. He holds a PhD in Machine Learning, and has worked with biological data since 2002.

Jacob has worked as a scientific researcher at University College London and University of Oxford. and has co-authored over 50 scientific papers with a deep knowledge of antibodies and TCRs.

Robert Ladner (CEO of CV6 Therapeutics)

Robert Ladner

CEO of CV6 Therapeutics
Kath Mackay (Director of Life Sciences at Bruntwood SciTech)

Kath Mackay

Director of Life Sciences at Bruntwood SciTech

Dr Kath Mackay is Director of Life Sciences for Bruntwood SciTech - the UK’s leading property provider dedicated to driving the growth of the UK science and technology sector. She has a keen interest in growing the life science industry, and businesses and infrastructure within the sector, ensuring the UK is the best place to establish and scale a life science organisation.

As Director of Life Sciences, Kath is responsible for developing the life science vision and strategy for Bruntwood SciTech, external affairs, and developing sector specific innovation services and investment support for the life sciences business across our network of campuses. Kath also oversees Alderley Park - the UK’s largest single- site life science campus - the new £210m Birmingham Health Innovation Campus, and Citylabs in Manchester, the world-leading health innovation and precision medicine campus in partnership with Manchester University NHS Foundation Trust.
Kath joined Bruntwood SciTech from the executive board of Innovate UK where she led the team responsible for growing and scaling businesses working in the biomedical, health, agriculture and food sectors, creating and delivering a £700m portfolio of infrastructure, Catapults, grant and loan investments. Kath is also Non-Executive Director of the Northern Health Science Alliance, the North of England’s health partnership, UKRI’s National Biofilms Innovation Centre, and Cheshire and Warrington Local Enterprise Partnership.

MM

Michael Malecki

President & CEO of Apex Market Access
Damian Marron (Head of Biopharma at Treehill Partners Ltd)

Damian Marron

Head of Biopharma at Treehill Partners Ltd
Gino Martini (CEO of Precision Health Technologies Accelerator Ltd (PHTA))

Gino Martini

CEO of Precision Health Technologies Accelerator Ltd (PHTA)
Ramsay McFarlane (Doctor / CEO of Awen Oncology Limited)

Ramsay McFarlane

Doctor / CEO of Awen Oncology Limited
Andrew Mullen (CEO of Charco Neurotech)

Andrew Mullen

CEO of Charco Neurotech
Ufuk Nalbantoğlu (CTO at Enbiosis)

Ufuk Nalbantoğlu

CTO at Enbiosis
Ashwin Nandakumar (CEO & Co-Founder of Granza BIo)

Ashwin Nandakumar

CEO & Co-Founder of Granza BIo
Jon Rees (Co-Founder & Senior Discovery Scientist of MitoRx Therapeutics)

Jon Rees

Co-Founder & Senior Discovery Scientist of MitoRx Therapeutics
Stuart Rose (CEO of OBN)

Stuart Rose

CEO of OBN
Karin Schmitt (Chief Operating Officer at Mursla Bio)

Karin Schmitt

Chief Operating Officer at Mursla Bio
Nik Sharma (Co-Founder CEO of BioCorteX)

Nik Sharma

Co-Founder CEO of BioCorteX
Nadia Shivji-Brown (Senior Business Development Manager at UK Health Security Agency)

Nadia Shivji-Brown

Senior Business Development Manager at UK Health Security Agency
MT

Marina Tarunina

Research Director of Plasticell
Janette Thomas (CEO of Five Alarm Bio Ltd)

Janette Thomas

CEO of Five Alarm Bio Ltd
Mihriban Tuna (CEO of Immutrin)

Mihriban Tuna

CEO of Immutrin

Mihriban is an executive leader with over 20 years’ experience in biologics drug development across biotech and pharma. She is currently CEO of Immutrin and Entrepreneur in Residence at Cambridge Innovation Capital.

Previously, Mihriban was Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda), Senior Vice President of Drug Discovery at F-star Therapeutics and an early employee at Domantis (acquired by GSK).

Mihriban holds a BSc in Biology from Middle East Technical University, a PhD in Biochemistry from University of Sussex and an EMBA from University of Cambridge Judge Business School.

Mel Walker (Managing Director of BioPharma Futures)

Mel Walker

Managing Director of BioPharma Futures
David Weinkove (CSO at Magnitude Biosciences)

David Weinkove

CSO at Magnitude Biosciences

David Weinkove has worked in the field of ageing for over 25 years and is the Chair of the British Society for Research on Ageing. He is also a Professor in the Department of Biosciences at Durham University, where he researches how bacteria impact ageing using the nematode worm C. elegans as a fast-ageing in vivo model. In 2018, David co-founded Magnitude Biosciences to apply to the power of the C. elegans and automated imaging technology to industrial drug discovery. As Chief Scientific Officer, David helps clients find solutions to their drug discovery challenges using C. elegans where possible.

Craig Woods (CEO of Forge Genetics Ltd)

Craig Woods

CEO of Forge Genetics Ltd